Aspirin (Low-dose)
Treatment for Coronary Artery Disease
Typical Dosage: 75-100mg daily
Effectiveness
80%
Safety Score
80%
Clinical Trials
66
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-100mg daily
Time to Effect
immediate antiplatelet effect, clinical benefit over months-years
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
80(Treat 80 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
300(Treat 300 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15
Monitoring:$20
Side Effect Mgmt:$30
Total Annual:$65
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$500/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$433
Comparison vs No Treatment
Cost Difference
$-65/year
Less expensive
QALY Difference
+0.08 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Aspirin (Low-dose) Outcomes
for Coronary Artery Disease
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+15%
Common Side Effects
Gastrointestinal bleeding
+1.5%
Dyspepsia
+5%
Hemorrhagic stroke
+0.05%
Active Clinical Trials
5 active trials recruiting for Aspirin (Low-dose) in Coronary Artery Disease
Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)
NCT07195149RECRUITINGPHASE3
1.7K participants
INTERVENTIONAL
Bialystok, Poland +17 more
Started: Nov 25, 2025
One-Month DAPT in CABG Patients
NCT05997693RECRUITINGPHASE3
700 participants
INTERVENTIONAL
Englewood, United States +21 more
Started: Aug 15, 2024
Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease
NCT06541691RECRUITINGNA
3K participants
INTERVENTIONAL
Tehran, Iran
Started: Mar 6, 2024
Aspirin Dose Comparison in Elderly PCI Patients: 30mg vs. 75mg in Acute Coronary Syndrome
NCT06254391RECRUITINGPHASE2
40 participants
INTERVENTIONAL
Warsaw, Poland
Started: Jul 3, 2023
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
NCT06228456RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Jacksonville, United States
Started: Apr 1, 2024
Completed Clinical Trials
8 completed trials for Aspirin (Low-dose) in Coronary Artery Disease
Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery
NCT02209909COMPLETEDNA
48 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jul 1, 2014
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
NCT02567461COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Jacksonville, United States
Started: Mar 1, 2016
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
NCT04006288COMPLETEDPHASE4
90 participants
INTERVENTIONAL
Jacksonville, United States
Started: Sep 6, 2019
Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan)
NCT01212302COMPLETEDNA
500 participants
INTERVENTIONAL
Bochum, Germany
Started: Oct 1, 2008
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies
NCT03718429COMPLETEDPHASE4
86 participants
INTERVENTIONAL
Jacksonville, United States +1 more
Started: Jan 14, 2019
Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation
NCT05797376COMPLETEDPHASE4
92 participants
INTERVENTIONAL
Seoul, South Korea
Started: Aug 24, 2021
Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
NCT04753372COMPLETED
645 participants
OBSERVATIONAL
's-Hertogenbosch, Netherlands +11 more
Started: Dec 21, 2020
Optimum Platelet Inhibition After Coronary Bypass Surgery
NCT00262275COMPLETEDNA
INTERVENTIONAL
Cambridge, United Kingdom
Started: Jul 1, 2002
Showing 20 of 66 total trials